Lifesaving therapy offers hope for patients with advanced heart failure, serving as a bridge to heart transplantation or long-term therapy. WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- MedStar Washington ...

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...

ORLANDO, FL—The latest-generation HeartMate left ventricular assist device has beat out its predecessor with results so promising that at least one observer is raising the question of whether it’s ...

ORLANDO -- The HeartMate 3 advantage appears durable to 2 years, with still no pump thrombosis requiring reoperation and fewer replacements or disabling strokes compared with the prior-generation ...

ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company's HeartMate 3™ heart pump ...

In the ROADMAP study, patients with a HeartMate II ™ LVAD had a functional improvement in quality of life compared to optimal medical management The ROADMAP study was a prospective, multi-center ...

When Dr. Robert Kormos, a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, as division ...

Abbott Laboratories' HeartMate 3 heart pump for advanced heart failure kept more patients alive for two years with fewer incidents of stroke than the company's prior left ventricular assist device ...

With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.

CLEVELAND, OH — Researchers are warning about "unexpectedly" and "abruptly" increased rates of thrombosis with the HeartMate II (Thoratec) left ventricular assist device (LVAD) occurring early after ...

The HeartMate 3 (Abbott) left ventricular assist device (LVAD) can now be used in pediatric patients with advanced refractory left ventricular heart failure who are awaiting heart transplantation or ...